

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 June 2024 (13.06.2024)



(10) International Publication Number
WO 2024/121233 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 13/12 (2006.01)
A61K 39/395 (2006.01) A61P 37/02 (2006.01)

(21) International Application Number:

PCT/EP2023/084528

(22) International Filing Date:

06 December 2023 (06.12.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2218388.3 07 December 2022 (07.12.2022) GB

(71) Applicant: **VVB BIO PTE. LTD.** [SG/SG]; 11 Collyer Quay, #17-00 The Arcade, Singapore 049317 (SG).

(71) Applicant (for LS only): **CLEGG, Richard Ian** [GB/GB]; Aurora Building, Counterslip, Bristol Avon BS1 6BX (GB).

(72) Inventors: **SCHAEFER, Sebastian**; c/o VVB Bio Pte. Ltd., 11 Collyer Quay, #17-00 The Arcade, Singapore 049317 (SG). **COOK, Stuart Alexander**; c/o VVB Bio Pte. Ltd., 11 Collyer Quay, #17-00 The Arcade, Singapore 049317 (SG).

(74) Agent: **MEWBURN ELLIS LLP**; Aurora Building, Counterslip, Bristol BS1 6BX (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

(54) Title: GP130 ANTIGEN-BINDING MOLECULES

gp130 mAb binders on Mouse atrial fibroblasts			
rmll11	Antibody Candidate	% of activated fibroblasts	Activated fibroblasts (norm.)
-	-	20.9%	1.00
24h	-	50.0%	2.39
24h	Industry Standard	22.3%	1.07
24h	CSP-3G9	22.7%	1.09
24h	CSP-4A7	44.4%	2.12
24h	CSP-7D8	46.6%	2.23
24h	CSP-8C6	21.7%	1.04

Figure 1A

(57) Abstract: Gp130 antigen-binding molecules are disclosed. Also disclosed are nucleic acids and expression vectors encoding, compositions comprising, and methods using, the Gp130 antigen-binding molecules.

WO 2024/121233 A1